SEC Form 4 · accession 0001209191-15-053219
Conatus Pharmaceuticals Inc. · CNAT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David F Hale
Director
Period of report
Jun 11, 2015
Accepted (ET)
Jun 15, 2015 · 4:06 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001383701
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $5.52 | Jun 11, 2015 | A | 35,000 | A | — | Jun 10, 2025 | Common Stock | 35,000 | 35,000 | D |
Explanation of responses
- F1The shares subject to this option become exercisable as the shares vest. The entire number of shares subject to this option becomes fully vested and exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service on the board of directors of the Issuer through such vesting date.